ArticleNature medicine2022
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
19.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 134 citations in OpenAlex.
- Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.Nature medicine · 2024Trial
- Genomic architecture of IRF4 rearrangements in childhood and adult large B-cell lymphomas.Blood advances · 2026Article
- Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.Blood cancer discovery · 2026Article
- Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.British journal of haematology · 2026Article
- High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model.HemaSphere · 2026Article
- Clonotypic characterization defines B-cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies.HemaSphere · 2026Article
- Follicular Lymphoma Transformation is Characterized by Cytokine-associated Remodeling of Stromal and Macrophage Compartments.Cancer discovery · 2026Article
- Article
- Genotype-to-Phenotype Mapping of Somatic Clonal Mosaicism via Single-Cell Co-Capture of DNA Mutations and mRNA Transcripts.Cancer discovery · 2026Article
- Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.Nature communications · 2026Article
- Article
- Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.Leukemia · 2026Article
- Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy.Clinical and translational medicine · 2026Review
- [CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation for diffuse large B-cell Richter syndrome: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Molecular Pathogenesis and Targeted Treatment of Richter Transformation.Biomedicines · 2026Review
- Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.Cell genomics · 2026Article
- IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia.HemaSphere · 2026Article
- Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative review.Contemporary oncology (Poznan, Poland) · 2026Review
- Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.bioRxiv : the preprint server for biology · 2025Article
- Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies.Cell death & disease · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 17 institutions in 5 countries.
Ferran Nadeu *Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. nadeu@recerca.clinic.cat.ORCID http://orcid.org/0000-0003-2910-9440
Romina Royo *Barcelona Supercomputing Center (BSC), Barcelona, Spain.ORCID http://orcid.org/0000-0003-3493-0874
Ramon Massoni-Badosa *CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Heribert Playa-Albinyana *Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0002-3447-3848
Beatriz Garcia-Torre *Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Martí Duran-FerrerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0003-1666-5819
Kevin J DawsonWellcome Sanger Institute, Hinxton, UK.
Marta KulisInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Ander Diaz-NavarroCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Neus VillamorInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Juan L MeleroOmniscope, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1387-6231
Vicente ChapaprietaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0002-4910-5394
Ana Dueso-BarrosoBarcelona Supercomputing Center (BSC), Barcelona, Spain.ORCID http://orcid.org/0000-0003-2000-9718
Julio DelgadoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Riccardo MoiaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.ORCID http://orcid.org/0000-0001-7393-1138
Sara Ruiz-GilCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Domenica MarcheseCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Ariadna GiróInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Núria Verdaguer-DotInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Mónica RomoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Guillem ClotInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0003-2588-7413
Maria RozmanInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Gerard FrigolaHospital Clínic of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6794-6456
Alfredo Rivas-DelgadoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0003-0385-3415
Tycho BaumannCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Miguel AlcocebaCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.ORCID http://orcid.org/0000-0002-3819-4846
Marcos GonzálezCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Fina ClimentHospital Universitari de Bellvitge-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Pau AbrisquetaDepartment of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Josep CastellvíDepartment of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5745-9996
Francesc BoschDepartment of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Marta AymerichInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Anna EnjuanesInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Sílvia Ruiz-GaspàInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Armando López-GuillermoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Pedro JaresInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Sílvia BeàInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7192-2385
Salvador Capella-GutierrezBarcelona Supercomputing Center (BSC), Barcelona, Spain.ORCID http://orcid.org/0000-0002-0309-604X
Josep Ll GelpíBarcelona Supercomputing Center (BSC), Barcelona, Spain.
Núria López-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4925-8988
David TorrentsBarcelona Supercomputing Center (BSC), Barcelona, Spain.
Peter J CampbellWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0002-3921-0510
Ivo GutCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7219-632X
Davide RossiOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.ORCID http://orcid.org/0000-0002-4681-0151
Xose S PuenteCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.ORCID http://orcid.org/0000-0001-9525-1483
Pablo M Garcia-RovesUniversitat de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8371-2067
Dolors ColomerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7486-8484
Holger HeynCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-3276-1889
Francesco MauraMyeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0000-0002-5017-1620
José I Martín-SuberoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-8809-5195
Elías CampoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ecampo@clinic.cat.ORCID http://orcid.org/0000-0001-9850-9793
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESCentro de Investigación Biomédica en Red de Cáncer · ESBarcelona Supercomputing Center · ESCentre for Genomic Regulation · ESInstitució Catalana de Recerca i Estudis Avançats · ESVall d'Hebron Hospital Universitari · ESInstituto de Investigación Biomédica de Salamanca · ESUniversidad de Oviedo · ESUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversitat Pompeu Fabra · ESWellcome Sanger Institute · GBBellvitge University Hospital · ESHospital Universitario 12 De Octubre · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstitute of Oncology Research · CHUniversity of Miami · US
Funding
Cancer Research UK
Abstract
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseCell Transformation, NeoplasticDisease ProgressionHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.